De Novo heart failure with reduced ejection fraction - Drissa, Mariem
39,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
20 °P sammeln
  • Broschiertes Buch

Heart failure is a serious and common disease, with an estimated prevalence of 1 to 2% in industrialised countries. In recent years, its prevalence has steadily increased worldwide. It represents a major public health problem because of its frequency and its consequences in terms of morbidity and mortality, and because of its considerable economic impact on the healthcare system. It remains a topical issue because of the enormous therapeutic advances made in its management in recent years.The aim of this study was to determine the epidemiological, clinical, therapeutic and evolutionary…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Heart failure is a serious and common disease, with an estimated prevalence of 1 to 2% in industrialised countries. In recent years, its prevalence has steadily increased worldwide. It represents a major public health problem because of its frequency and its consequences in terms of morbidity and mortality, and because of its considerable economic impact on the healthcare system. It remains a topical issue because of the enormous therapeutic advances made in its management in recent years.The aim of this study was to determine the epidemiological, clinical, therapeutic and evolutionary characteristics of newly diagnosed (de Novo) heart failure with reduced LVEF, and to study the extent to which the management of heart failure complies with international recommendations.
Autorenporträt
Dr. Drissa Mariem, Professorin für Kardiologie an der Medizinischen Fakultät Tunis und Schatzmeisterin der tunesischen Gesellschaft für Kardiologie und kardiovaskuläre Chirurgie.